RE:BioCloud and OlympicsJust a reminder, it was 20,000 units monthly, not annually. Many of us with this scenario viewed it as a fantastic investment for even selling 20,000 annually instead of 240,000. The projection for the 9 months was in the neighbourhood of 1,000 compared to the 180,000 capacity. KNR's assessment of the market and its product was a bust that resulted in our investment bust. Nothing but facts.
LivingTheDream1 wrote: I would have to say that it is pretty clear by now that one should not get too excited about successful BioCloud sales numbers coming out from the Olympics. KNR has had ample opportunity to promote and sell BioCloud throughout the covid pandemic and it has been a colossal failure so far. Sales are almost non-existent versus the 20,000 or so annual production capacity that management has been teasing the market with. What will change with the Olympics? All the money spent on hiring various PR firms to promote the BioCloud product has done nothing to kickstart sales to date and nothing of substance appears to be coming. For those promoting BioCloud as an "investment of a lifetime" one really has to question their motive. The rollout of BioCloud has been a bust. The proof is in the results. KNRs base business looks like it may have some legs but in my mind there is still much to prove. I could see a mid $1.50 price target by yearend but going much higher than this is not supported based on what I am seeing.